You just read:

Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults with Type 2 Diabetes

News provided by

Novo Nordisk

Jun 12, 2016, 10:15 ET